Literature DB >> 30089516

Correction to: Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.

Rubén Rodríguez Bautista1,2, Alette Ortega Gómez3, Alfredo Hidalgo Miranda4, Alejandro Zentella Dehesa5, Cynthia Villarreal-Garza6, Federico Ávila-Moreno7,8, Oscar Arrieta1.   

Abstract

Upon publication of the original article [1], the authors noticed that the Figs. 1, 2 and 3 were incorrectly given.

Entities:  

Year:  2018        PMID: 30089516      PMCID: PMC6083633          DOI: 10.1186/s13148-018-0537-5

Source DB:  PubMed          Journal:  Clin Epigenetics        ISSN: 1868-7075            Impact factor:   6.551


Correction

Upon publication of the original article [1], the authors noticed that the Figs. 1, 2 and 3 were incorrectly given. The correct Figs. 1, 2 and 3 are given below.
Fig. 1

Proposed five functional archetypes for the lncRNA mechanisms. 1. Decoys: lncRNAs can titrate away transcription factors and other proteins away from chromatin, or titrate the protein factors into nuclear subdomains. 2. Signals: lncRNAs expression can faithfully reflect the combinatorial actions of transcription factors (colored ovals) or signaling pathways to indicate gene regulation by space and time. 3. Guides: lncRNAs may recruit chromatin-modifying enzymes to gene-promoter targets, either in Cis (near the genetic region of the lncRNA transcription) or in Trans into distant target genes. 4. Scaffolds: lncRNAs may bring together multiple proteins to conform ribonucleoprotein complexes. The lncRNA-RNP may act on chromatin as illustrated to affect histone code modifications. In other instances, the lncRNA scaffold is structural and stabilizes nuclear structures or signaling complexes 5. Sponge: lncRNAs that by complementarity of bases succeed in matching or sequestering sequences of small non-coding RNAs, such as miRNAs, are controlling bioavailability of miRNAs, vs. lncRNAs themselves, with the functional biological repercussions at cellular or physiological level. RNA-induced silencing complex RISC

Fig. 2

A molecular mechanism model for lncRNAs involved in the tumorigenesis of human TNBC. a lincRNA-RoR as a miR-145 inhibitor (oncogene miRNA). b MALAT1 as a competitive endogenous RNA of miR-1 (tumor suppressor miRNA). c LINK-A as a component of ribonucleoprotein complexes, example shows the regulations of HIF1α pathway. ARF6 ADP-ribosylation factor 6, UTR 3′ untranslated region 3, RISC RNA-induced silencing complex, HB-EGF heparin-binding EGF-like growth factor, EGFR epidermal growth factor receptor, GPNMB transmembrane glycoprotein NMB, BLK B lymphocyte kinase, LRRK2 leucine-rich repeat kinase 2, HIF1α hypoxia-inducible factor 1-alpha, vascular endothelial growth factor VEGF, iNOS inducible nitric oxide synthase, IGF-2 insulin-like growth factor 2, RNP ribonucleoprotein

Fig. 3

Epigenetic implications of lncRNAs in the development of TNBC. a MALAT1 regulated by KDM5B and has-miR-448. b LOC554202 as a host gene of miR-31 (tumor suppressor miRNA), WAVE3 (WAS protein family member 3) KDM5B (lysine-specific demethylase 5B also known as histone demethylase JARID1B), H3K4me3 (trimethylation of lysine 4 on the histone H3 protein subunit), H3K4me1 (monomethylation of lysine 4 on the histone H3 protein subunit), hsa-miR-448 (also known miRNA448), BRCA1/2 (breast cancer 1/2), pRB (retinoblastoma protein), CAV 1 (caveolin 1) HOXA5 (Homeobox protein Hox-A5), SFN (Stratifin), CH3 (methyl group), and RhoA (Ras homolog gene family, member A)

Proposed five functional archetypes for the lncRNA mechanisms. 1. Decoys: lncRNAs can titrate away transcription factors and other proteins away from chromatin, or titrate the protein factors into nuclear subdomains. 2. Signals: lncRNAs expression can faithfully reflect the combinatorial actions of transcription factors (colored ovals) or signaling pathways to indicate gene regulation by space and time. 3. Guides: lncRNAs may recruit chromatin-modifying enzymes to gene-promoter targets, either in Cis (near the genetic region of the lncRNA transcription) or in Trans into distant target genes. 4. Scaffolds: lncRNAs may bring together multiple proteins to conform ribonucleoprotein complexes. The lncRNA-RNP may act on chromatin as illustrated to affect histone code modifications. In other instances, the lncRNA scaffold is structural and stabilizes nuclear structures or signaling complexes 5. Sponge: lncRNAs that by complementarity of bases succeed in matching or sequestering sequences of small non-coding RNAs, such as miRNAs, are controlling bioavailability of miRNAs, vs. lncRNAs themselves, with the functional biological repercussions at cellular or physiological level. RNA-induced silencing complex RISC A molecular mechanism model for lncRNAs involved in the tumorigenesis of human TNBC. a lincRNA-RoR as a miR-145 inhibitor (oncogene miRNA). b MALAT1 as a competitive endogenous RNA of miR-1 (tumor suppressor miRNA). c LINK-A as a component of ribonucleoprotein complexes, example shows the regulations of HIF1α pathway. ARF6 ADP-ribosylation factor 6, UTR 3′ untranslated region 3, RISC RNA-induced silencing complex, HB-EGF heparin-binding EGF-like growth factor, EGFR epidermal growth factor receptor, GPNMB transmembrane glycoprotein NMB, BLK B lymphocyte kinase, LRRK2 leucine-rich repeat kinase 2, HIF1α hypoxia-inducible factor 1-alpha, vascular endothelial growth factor VEGF, iNOS inducible nitric oxide synthase, IGF-2 insulin-like growth factor 2, RNP ribonucleoprotein Epigenetic implications of lncRNAs in the development of TNBC. a MALAT1 regulated by KDM5B and has-miR-448. b LOC554202 as a host gene of miR-31 (tumor suppressor miRNA), WAVE3 (WAS protein family member 3) KDM5B (lysine-specific demethylase 5B also known as histone demethylase JARID1B), H3K4me3 (trimethylation of lysine 4 on the histone H3 protein subunit), H3K4me1 (monomethylation of lysine 4 on the histone H3 protein subunit), hsa-miR-448 (also known miRNA448), BRCA1/2 (breast cancer 1/2), pRB (retinoblastoma protein), CAV 1 (caveolin 1) HOXA5 (Homeobox protein Hox-A5), SFN (Stratifin), CH3 (methyl group), and RhoA (Ras homolog gene family, member A) The original article has been corrected.
  1 in total

Review 1.  Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.

Authors:  Rubén Rodríguez Bautista; Alette Ortega Gómez; Alfredo Hidalgo Miranda; Alejandro Zentella Dehesa; Cynthia Villarreal-Garza; Federico Ávila-Moreno; Oscar Arrieta
Journal:  Clin Epigenetics       Date:  2018-06-27       Impact factor: 6.551

  1 in total
  6 in total

Review 1.  Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance.

Authors:  Sangita Sridharan; Cory M Howard; Augustus M C Tilley; Boopathi Subramaniyan; Amit K Tiwari; Randall J Ruch; Dayanidhi Raman
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

2.  LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2.

Authors:  Na Huang; Wei Guo; Ke Ren; Wancheng Li; Yi Jiang; Jian Sun; Wenjing Dai; Wei Zhao
Journal:  Front Oncol       Date:  2019-10-22       Impact factor: 6.244

3.  LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.

Authors:  Chuang Du; Yan Wang; Yingying Zhang; Jianhua Zhang; Linfeng Zhang; Jingruo Li
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 4.  Interleukin‑6 signalling as a valuable cornerstone for molecular medicine (Review).

Authors:  Maria Trovato; Salvatore Sciacchitano; Alessio Facciolà; Andrea Valenti; Giuseppa Visalli; Angela Di Pietro
Journal:  Int J Mol Med       Date:  2021-04-28       Impact factor: 4.101

5.  TP53-Activated lncRNA GHRLOS Regulates Cell Proliferation, Invasion, and Apoptosis of Non-Small Cell Lung Cancer by Modulating the miR-346/APC Axis.

Authors:  Ke Ren; Jinghui Sun; Lingling Liu; Yuping Yang; Honghui Li; Zhichao Wang; Jingzhu Deng; Min Hou; Jia Qiu; Wei Zhao
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

6.  Profiling non-coding RNA levels with clinical classifiers in pediatric Crohn's disease.

Authors:  Ranjit Pelia; Suresh Venkateswaran; Jason D Matthews; Yael Haberman; David J Cutler; Jeffrey S Hyams; Lee A Denson; Subra Kugathasan
Journal:  BMC Med Genomics       Date:  2021-07-29       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.